Advanced Lung Cancer
Conditions
Interventions
Dose of each agent was escalated according to the schedule below. Combination A Day 1 2 3 4 5 CDDP x TPT x x x x PTX x Lenograstim x Combination B Day 1 2 3 4 5 CDDP x AMR x x
Sponsors
Niigata Lung Cancer Treatment Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) StageIIIB/IV lung cancer proven by histology and/or cytology 2) ineligible for curative RT 3) No prior chemotherapy 4) Age 20<= <70 years PS 0-2 5) At least one or more measurable lesion by RECIST 6) Adequate organ function 7) Life expectancy more than three months. 8) Written Informed Consent
Exclusion criteria
Exclusion criteria: Patients were excluded if they had any active concomitant malignancies, symptomatic brain metastases, past history of severe allergic reactions to drugs, interstitial pneumonia identified by chest X-ray, superior vena cava syndrome, or other serious complications, such as uncontrolled angina pectoris, myocardial infarction within 3 months, heart failure, uncontrolled diabetes mellitus or hypertension, uncontrolled massive pleural effusion or ascites.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1)DLT 2)MTD,RD | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)toxicity 2)tumor response | — |
Countries
Japan
Contacts
Public ContactSatoshi Watanabe
Niigata University Medical and Dental Hospital Department of Respiratory Medicine and Infectious Diseases
Outcome results
None listed